Stada Ranibizumab Deal Doesn’t Change Coherus’ Aspirations

Coherus Looking To Refile By End Of Year

 
• By Dean Rudge
Eye
Coherus has high hopes for the biosimilar ophthalmology market in the US • Source: Shutterstock

More from Biosimilars

More from Products